NCT01209299已完成不适用
Integrated Molecular Signature for the Prediction of Response to Carboplatin/Paclitaxel-Based Chemotherapy in Metastatic Melanoma
ECOG-ACRIN Cancer Research Group0 个研究点目标入组 80 人开始时间: 2012年1月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 主要终点
- Correlation between gene expression and promoter methylation profiles to chemotherapy response
研究概览
简要总结
RATIONALE: Studying samples of tissue in the laboratory from patients receiving carboplatin and paclitaxel with or without sorafenib tosylate may help doctors learn more about the effects of this treatment on cells. It may also help doctors understand how well patients respond to treatment.
PURPOSE: This research study is studying biomarkers in predicting response to chemotherapy in patients with advanced or metastatic melanoma previously treated with carboplatin and paclitaxel with or without sorafenib tosylate.
详细描述
OBJECTIVES:
- To independently correlate the gene expression and promoter methylation profiles to chemotherapy response in patients with advanced or metastatic melanoma treated with carboplatin and paclitaxel with versus without sorafenib on clinical trial ECOG-E2603.
- To develop a predictive model of chemotherapy response utilizing integrated analysis of gene expression and promoter methylation data.
- To evaluate whether the NER pathway haplotypes are associated with platinum drug resistance and survival.
OUTLINE: This is a multicenter study.
Archived paraffin-embedded tissue samples are analyzed for gene expression and promoter methylation profiles, and genes involved in the NER pathway.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Correlation between gene expression and promoter methylation profiles to chemotherapy response
时间窗: 1 month
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone LymphomaSplenic Marginal Zone LymphomaNCT02945319International Extranodal Lymphoma Study Group (IELSG)373
招募中
不适用
Correlation of Molecular Markers With Response to Therapy and Breast Cancer BehaviorBreast CancerNCT01000883UNC Lineberger Comprehensive Cancer Center10,000
已完成
1 期
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer PatientsNon Small Cell Lung CancerCancerNCT00708448University of Utah26
Unknown
2 期
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving OxaliplatinChemotherapeutic Agent ToxicityNeurotoxicityColorectal CancerNCT00884767Institut Cancerologie de l'Ouest206
终止
1 期
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8Ann Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate CarcinomaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid System NeoplasmLocally Advanced Pancreatic AdenocarcinomaMetastatic Breast CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Pancreatic AdenocarcinomaMyelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and ThrombocytosisMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Hematologic MalignancyRecurrent Hodgkin LymphomaRecurrent Myelodysplastic SyndromeRecurrent Myelodysplastic/Myeloproliferative NeoplasmRecurrent Myeloproliferative NeoplasmRecurrent Non-Hodgkin LymphomaRecurrent Plasma Cell MyelomaRecurrent Small Lymphocytic LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Lymphocytic LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Hematologic MalignancyRefractory Hodgkin LymphomaRefractory Malignant Solid NeoplasmRefractory Myelodysplastic SyndromeRefractory Myelodysplastic/Myeloproliferative NeoplasmRefractory Non-Hodgkin LymphomaRefractory Plasma Cell MyelomaRefractory Primary MyelofibrosisRefractory Small Lymphocytic LymphomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Unresectable Pancreatic AdenocarcinomaPrimary MyelofibrosisNCT03878524OHSU Knight Cancer Institute2